Bayesian analysis and risk assessment in genetic counseling and testing

被引:19
作者
Ogino, S
Wilson, RB
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
[4] Univ Penn, Ctr Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/S1525-1578(10)60484-9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Risk assessment is an essential component of genetic counseling and testing, and Bayesian analysis plays a central role in genetic risk assessment. Bayesian analysis allows calculation of the probability of a particular hypothesis, either disease or carrier status, based on family information and/or genetic test results. Genetic risk should be assessed as accurately as possible for family decision making. Additional information, from the pedigree and/or from genetic testing, can often dramatically improve the accuracy of genetic risk assessment. We illustrate herein the application of Bayes' theorem and describe important basic principles in genetic risk assessment.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 19 条
[1]  
BAYES T, 1958, BIOMETRIKA, V45, P296
[2]   Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening [J].
Bobadilla, JL ;
Macek, M ;
Fine, JP ;
Farrell, PM .
HUMAN MUTATION, 2002, 19 (06) :575-606
[3]   RISK TABLES FOR GENETIC-COUNSELING IN SOME COMMON CONGENITAL MALFORMATIONS [J].
BONAITIPELIL, C ;
SMITH, C .
JOURNAL OF MEDICAL GENETICS, 1974, 11 (04) :374-377
[4]  
Bridge PJ, 1997, CALCULATION GENETIC
[5]  
Flodman P, 2001, AM J MED GENET, V100, P169, DOI 10.1002/1096-8628(20010422)100:2<169::AID-AJMG1243>3.0.CO
[6]  
2-K
[7]   Cystic fibrosis population carrier screening: Here at last-Are we ready? [J].
Grody, WW ;
Desnick, RJ .
GENETICS IN MEDICINE, 2001, 3 (02) :87-90
[8]  
Hodge S E, 1998, J Genet Couns, V7, P235, DOI 10.1023/A:1022843223026
[9]  
KING RA, 1992, GENETIC BASIS COMMON
[10]  
Korf BR, 1996, J CLIN LAB ANAL, V10, P368, DOI 10.1002/(SICI)1098-2825(1996)10:6<368::AID-JCLA8>3.0.CO